A proposal for a study on treatment selection and lifestyle recommendations in chronic inflammatory diseases: A danish multidisciplinary collaboration on prognostic factors and personalised medicine

Vibeke Andersen; Uffe Holmskov; Signe Bek Sørensen; Mohamad Jawhara; Karina W. Andersen; Anette Bygum; Lone Hvid; Jakob Grauslund; Jimmi Wied; Henning Glerup; Ulrich Fredberg; Jan Alexander Villadsen; Søren Geill Kjær; Jan Fallingborg; Seyed A.G.R. Moghadd; Torben Knudsen; Jacob Brodersen; Jesper Frøjk; Jens F. Dahlerup; Ole Haagen Nielsen; Robin Christensen; Anders Bo Bojesen; Grith Lykke Sorensen; Steffen Thiel; Nils J. Færgeman; Ivan Brandslund; Allan Stensballe; Erik Berg Schmidt; Andre Franke; David Ellinghaus; Philip Rosenstiel; Jeroen Raes; Berit Heitmann; Mette Boye; Charlotte Lindgaard Nielsen; Lars Werner; Jens Kjeldsen; Torkell Ellingsen

doi:10.3390/nu9050499

A proposal for a study on treatment selection and lifestyle recommendations in chronic inflammatory diseases: A danish multidisciplinary collaboration on prognostic factors and personalised medicine

Vibeke Andersen^*, Uffe Holmskov, Signe Bek Sørensen, Mohamad Jawhara, Karina W. Andersen, Anette Bygum, Lone Hvid, Jakob Grauslund, Jimmi Wied, Henning Glerup, Ulrich Fredberg, Jan Alexander Villadsen, Søren Geill Kjær, Jan Fallingborg, Seyed A.G.R. Moghadd, Torben Knudsen, Jacob Brodersen, Jesper Frøjk, Jens F. Dahlerup, Ole Haagen NielsenRobin Christensen, Anders Bo Bojesen, Grith Lykke Sorensen, Steffen Thiel, Nils J. Færgeman, Ivan Brandslund, Allan Stensballe, Erik Berg Schmidt, Andre Franke, David Ellinghaus, Philip Rosenstiel, Jeroen Raes, Berit Heitmann, Mette Boye, Charlotte Lindgaard Nielsen, Lars Werner, Jens Kjeldsen, Torkell Ellingsen

^*Corresponding author af dette arbejde

11 Citationer (Scopus)

59 Downloads (Pure)

Abstract

Chronic inflammatory diseases (CIDs), including Crohn’s disease and ulcerative colitis (inflammatory bowel diseases, IBD), rheumatoid arthritis, psoriasis, psoriatic arthritis, spondyloarthritides, hidradenitis suppurativa, and immune-mediated uveitis, are treated with biologics targeting the pro-inflammatory molecule tumour necrosis factor-α (TNF) (i.e., TNF inhibitors). Approximately one-third of the patients do not respond to the treatment. Genetics and lifestyle may affect the treatment results. The aims of this multidisciplinary collaboration are to identify (1) molecular signatures of prognostic value to help tailor treatment decisions to an individual likely to initiate TNF inhibitor therapy, followed by (2) lifestyle factors that support achievement of optimised treatment outcome. This report describes the establishment of a cohort that aims to obtain this information. Clinical data including lifestyle and treatment response and biological specimens (blood, faeces, urine, and, in IBD patients, intestinal biopsies) are sampled prior to and while on TNF inhibitor therapy. Both hypothesis-driven and data-driven analyses will be performed according to pre-specified protocols including pathway analyses resulting from candidate gene expression analyses and global approaches (e.g., metabolomics, metagenomics, proteomics). The final purpose is to improve the lives of patients suffering from CIDs, by providing tools facilitating treatment selection and dietary recommendations likely to improve the clinical outcome.

Originalsprog	Engelsk
Artikelnummer	499
Tidsskrift	Nutrients
Vol/bind	9
Udgave nummer	5
Antal sider	16
ISSN	2072-6643
DOI	https://doi.org/10.3390/nu9050499
Status	Udgivet - maj 2017

Adgang til dokumentet

10.3390/nu9050499Licens: CC BY

A Proposal for a Study on Treatment Selection and Lifestyle Recommendations in Chronic Inflammatory Diseases: A Danish Multidisciplinary Collaboration on Prognostic Factors and Personalised MedicineForlagets udgivne version, 279 KBLicens: CC BY

Citationsformater

Andersen, V., Holmskov, U., Bek Sørensen, S., Jawhara, M., Andersen, K. W., Bygum, A., Hvid, L., Grauslund, J., Wied, J., Glerup, H., Fredberg, U., Villadsen, J. A., Kjær, S. G., Fallingborg, J., Moghadd, S. A. G. R., Knudsen, T., Brodersen, J., Frøjk, J., Dahlerup, J. F., ... Ellingsen, T. (2017). A proposal for a study on treatment selection and lifestyle recommendations in chronic inflammatory diseases: A danish multidisciplinary collaboration on prognostic factors and personalised medicine. Nutrients, 9(5), Artikel 499. https://doi.org/10.3390/nu9050499

A proposal for a study on treatment selection and lifestyle recommendations in chronic inflammatory diseases: A danish multidisciplinary collaboration on prognostic factors and personalised medicine. / Andersen, Vibeke; Holmskov, Uffe; Bek Sørensen, Signe et al.
I: Nutrients, Bind 9, Nr. 5, 499, 05.2017.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

Andersen, V, Holmskov, U, Bek Sørensen, S, Jawhara, M, Andersen, KW, Bygum, A, Hvid, L, Grauslund, J, Wied, J, Glerup, H, Fredberg, U, Villadsen, JA, Kjær, SG, Fallingborg, J, Moghadd, SAGR, Knudsen, T, Brodersen, J, Frøjk, J, Dahlerup, JF, Nielsen, OH, Christensen, R, Bo Bojesen, A, Sorensen, GL, Thiel, S, Færgeman, NJ, Brandslund, I, Stensballe, A, Schmidt, EB, Franke, A, Ellinghaus, D, Rosenstiel, P, Raes, J, Heitmann, B, Boye, M, Nielsen, CL, Werner, L, Kjeldsen, J & Ellingsen, T 2017, 'A proposal for a study on treatment selection and lifestyle recommendations in chronic inflammatory diseases: A danish multidisciplinary collaboration on prognostic factors and personalised medicine', Nutrients, bind 9, nr. 5, 499. https://doi.org/10.3390/nu9050499

@article{e2cf7fce109f4ff2ad936f8cb473a063,

title = "A proposal for a study on treatment selection and lifestyle recommendations in chronic inflammatory diseases: A danish multidisciplinary collaboration on prognostic factors and personalised medicine",

abstract = "Chronic inflammatory diseases (CIDs), including Crohn{\textquoteright}s disease and ulcerative colitis (inflammatory bowel diseases, IBD), rheumatoid arthritis, psoriasis, psoriatic arthritis, spondyloarthritides, hidradenitis suppurativa, and immune-mediated uveitis, are treated with biologics targeting the pro-inflammatory molecule tumour necrosis factor-α (TNF) (i.e., TNF inhibitors). Approximately one-third of the patients do not respond to the treatment. Genetics and lifestyle may affect the treatment results. The aims of this multidisciplinary collaboration are to identify (1) molecular signatures of prognostic value to help tailor treatment decisions to an individual likely to initiate TNF inhibitor therapy, followed by (2) lifestyle factors that support achievement of optimised treatment outcome. This report describes the establishment of a cohort that aims to obtain this information. Clinical data including lifestyle and treatment response and biological specimens (blood, faeces, urine, and, in IBD patients, intestinal biopsies) are sampled prior to and while on TNF inhibitor therapy. Both hypothesis-driven and data-driven analyses will be performed according to pre-specified protocols including pathway analyses resulting from candidate gene expression analyses and global approaches (e.g., metabolomics, metagenomics, proteomics). The final purpose is to improve the lives of patients suffering from CIDs, by providing tools facilitating treatment selection and dietary recommendations likely to improve the clinical outcome.",

keywords = "Biomarker, Exercise, Food, Molecular epidemiology, Patient related outcome measures (PROMs), Personalized medicine, Red meat, Smoking, Treatment outcome, Western style diet (WSD)",

author = "Vibeke Andersen and Uffe Holmskov and {Bek S{\o}rensen}, Signe and Mohamad Jawhara and Andersen, {Karina W.} and Anette Bygum and Lone Hvid and Jakob Grauslund and Jimmi Wied and Henning Glerup and Ulrich Fredberg and Villadsen, {Jan Alexander} and Kj{\ae}r, {S{\o}ren Geill} and Jan Fallingborg and Moghadd, {Seyed A.G.R.} and Torben Knudsen and Jacob Brodersen and Jesper Fr{\o}jk and Dahlerup, {Jens F.} and Nielsen, {Ole Haagen} and Robin Christensen and {Bo Bojesen}, Anders and Sorensen, {Grith Lykke} and Steffen Thiel and F{\ae}rgeman, {Nils J.} and Ivan Brandslund and Allan Stensballe and Schmidt, {Erik Berg} and Andre Franke and David Ellinghaus and Philip Rosenstiel and Jeroen Raes and Berit Heitmann and Mette Boye and Nielsen, {Charlotte Lindgaard} and Lars Werner and Jens Kjeldsen and Torkell Ellingsen",

year = "2017",

month = may,

doi = "10.3390/nu9050499",

language = "English",

volume = "9",

journal = "Nutrients",

issn = "2072-6643",

publisher = "M D P I AG",

number = "5",

}

TY - JOUR

T1 - A proposal for a study on treatment selection and lifestyle recommendations in chronic inflammatory diseases

T2 - A danish multidisciplinary collaboration on prognostic factors and personalised medicine

AU - Andersen, Vibeke

AU - Holmskov, Uffe

AU - Bek Sørensen, Signe

AU - Jawhara, Mohamad

AU - Andersen, Karina W.

AU - Bygum, Anette

AU - Hvid, Lone

AU - Grauslund, Jakob

AU - Wied, Jimmi

AU - Glerup, Henning

AU - Fredberg, Ulrich

AU - Villadsen, Jan Alexander

AU - Kjær, Søren Geill

AU - Fallingborg, Jan

AU - Moghadd, Seyed A.G.R.

AU - Knudsen, Torben

AU - Brodersen, Jacob

AU - Frøjk, Jesper

AU - Dahlerup, Jens F.

AU - Nielsen, Ole Haagen

AU - Christensen, Robin

AU - Bo Bojesen, Anders

AU - Sorensen, Grith Lykke

AU - Thiel, Steffen

AU - Færgeman, Nils J.

AU - Brandslund, Ivan

AU - Stensballe, Allan

AU - Schmidt, Erik Berg

AU - Franke, Andre

AU - Ellinghaus, David

AU - Rosenstiel, Philip

AU - Raes, Jeroen

AU - Heitmann, Berit

AU - Boye, Mette

AU - Nielsen, Charlotte Lindgaard

AU - Werner, Lars

AU - Kjeldsen, Jens

AU - Ellingsen, Torkell

PY - 2017/5

Y1 - 2017/5

N2 - Chronic inflammatory diseases (CIDs), including Crohn’s disease and ulcerative colitis (inflammatory bowel diseases, IBD), rheumatoid arthritis, psoriasis, psoriatic arthritis, spondyloarthritides, hidradenitis suppurativa, and immune-mediated uveitis, are treated with biologics targeting the pro-inflammatory molecule tumour necrosis factor-α (TNF) (i.e., TNF inhibitors). Approximately one-third of the patients do not respond to the treatment. Genetics and lifestyle may affect the treatment results. The aims of this multidisciplinary collaboration are to identify (1) molecular signatures of prognostic value to help tailor treatment decisions to an individual likely to initiate TNF inhibitor therapy, followed by (2) lifestyle factors that support achievement of optimised treatment outcome. This report describes the establishment of a cohort that aims to obtain this information. Clinical data including lifestyle and treatment response and biological specimens (blood, faeces, urine, and, in IBD patients, intestinal biopsies) are sampled prior to and while on TNF inhibitor therapy. Both hypothesis-driven and data-driven analyses will be performed according to pre-specified protocols including pathway analyses resulting from candidate gene expression analyses and global approaches (e.g., metabolomics, metagenomics, proteomics). The final purpose is to improve the lives of patients suffering from CIDs, by providing tools facilitating treatment selection and dietary recommendations likely to improve the clinical outcome.

AB - Chronic inflammatory diseases (CIDs), including Crohn’s disease and ulcerative colitis (inflammatory bowel diseases, IBD), rheumatoid arthritis, psoriasis, psoriatic arthritis, spondyloarthritides, hidradenitis suppurativa, and immune-mediated uveitis, are treated with biologics targeting the pro-inflammatory molecule tumour necrosis factor-α (TNF) (i.e., TNF inhibitors). Approximately one-third of the patients do not respond to the treatment. Genetics and lifestyle may affect the treatment results. The aims of this multidisciplinary collaboration are to identify (1) molecular signatures of prognostic value to help tailor treatment decisions to an individual likely to initiate TNF inhibitor therapy, followed by (2) lifestyle factors that support achievement of optimised treatment outcome. This report describes the establishment of a cohort that aims to obtain this information. Clinical data including lifestyle and treatment response and biological specimens (blood, faeces, urine, and, in IBD patients, intestinal biopsies) are sampled prior to and while on TNF inhibitor therapy. Both hypothesis-driven and data-driven analyses will be performed according to pre-specified protocols including pathway analyses resulting from candidate gene expression analyses and global approaches (e.g., metabolomics, metagenomics, proteomics). The final purpose is to improve the lives of patients suffering from CIDs, by providing tools facilitating treatment selection and dietary recommendations likely to improve the clinical outcome.

KW - Biomarker

KW - Exercise

KW - Food

KW - Molecular epidemiology

KW - Patient related outcome measures (PROMs)

KW - Personalized medicine

KW - Red meat

KW - Smoking

KW - Treatment outcome

KW - Western style diet (WSD)

U2 - 10.3390/nu9050499

DO - 10.3390/nu9050499

M3 - Journal article

C2 - 28505128

AN - SCOPUS:85019440395

SN - 2072-6643

VL - 9

JO - Nutrients

JF - Nutrients

IS - 5

M1 - 499

ER -

A proposal for a study on treatment selection and lifestyle recommendations in chronic inflammatory diseases: A danish multidisciplinary collaboration on prognostic factors and personalised medicine

Abstract

Adgang til dokumentet

Fingeraftryk

Citationsformater